Business Context and Reporting Period
Dianthus Therapeutics, Inc. (DNTH) is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune diseases. This Form 10-K covers the fiscal year ended December 31, 2025. The company's lead candidate, claseprubart, is a selective C1s inhibitor in Phase 2/3 trials for Generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN). A second candidate, DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor, entered Phase 1 trials in late 2025.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Total Revenues | $2.0 | $6.2 |
| Net Loss | $(162.3) | $(85.0) |
| Research & Development Expenses | $145.6 | $83.1 |
| General & Administrative Expenses | $34.3 | $25.0 |
| Cash, Cash Equivalents & Investments | $514.4 | $275.2 |
| Net Cash Used in Operating Activities | $(129.1) | $(78.2) |
| Net Cash Provided by Financing Activities | $280.1 | $255.6 |
Note: The company has no product revenue; all revenue is derived from licensing agreements.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately 67% to $2.0 million, primarily due to a reduction in reimbursable costs associated with the Zenas/Tenacia licensing agreements compared to 2024.
- Increased R&D Spend: R&D expenses rose 75% to $145.6 million. This was driven by a $30.0 million upfront and near-term milestone payment for the DNTH212 license from Nanjing Leads Biolabs and increased clinical operations for claseprubart.
- Capital Raise: In September 2025, the company completed an underwritten public offering raising gross proceeds of $288.4 million, significantly bolstering liquidity.
- Net Loss Expansion: Net loss more than doubled to $162.3 million, reflecting the surge in development costs and the new licensing commitment.
Guidance, Outlook, and Risks
Outlook and Milestones
- Claseprubart (gMG): Positive Phase 2 MaGic trial data reported in September 2025. Phase 3 registrational trial expected to initiate in mid-2026 with top-line results in H2 2028.
- Claseprubart (CIDP): Achieved an early "GO" decision in the Phase 3 CAPTIVATE trial in March 2026 (post-year-end) based on interim responder analysis.
- Claseprubart (MMN): Phase 2 MoMeNtum trial results expected in H2 2026.
- DNTH212: Phase 1 trial initiated in December 2025; results expected in H2 2026.
Liquidity
Management believes existing cash, cash equivalents, and investments of $514.4 million are sufficient to fund operations into 2028.
Key Risks
- Manufacturing Dependency: Reliance on WuXi Biologics (China) for manufacturing exposes the company to potential supply chain disruptions due to the BIOSECURE Act and geopolitical tensions.
- Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require additional capital to complete clinical trials and commercialization.
- Regulatory Uncertainty: Success depends on obtaining FDA and foreign regulatory approvals, which are inherently unpredictable.
Investor Verification Checklist
- Cash Runway: Verify the $514.4 million cash balance and the assumption that it funds operations through 2028 given the high burn rate.
- Manufacturing Strategy: Assess the company's specific mitigation plans regarding the BIOSECURE Act and reliance on WuXi Biologics.
- DNTH212 Commitment: Confirm the $30.0 million upfront payment to Nanjing Leads Biolabs and the remaining $8.0 million milestone obligation.
- Clinical Timelines: Monitor the initiation of the Phase 3 gMG trial in mid-2026 and the interim data readout for the CIDP trial.
- Licensing Revenue: Review the terms of the Tenacia agreement to understand future potential milestone and royalty revenue streams.